3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: A potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity

Journal of Medicinal Chemistry

Volumn 46, Issue 2, 2003, Pages 204-206

  Cosford, Nicholas D P ^a   Tehrani, Lida ^a   Roppe, Jeffrey ^a   Schweiger, Edwin ^a   Smith, Nicholas D ^a   Anderson, Jeffrey ^a   Bristow, Linda ^a   Brodkin, Jesse ^a   Jiang, Xiaohui ^a   McDonald, Ian ^a   Rao, Sara ^a   Washburn, Mark ^a   Varney, Mark A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR 5; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CHEMICAL REACTION; DRUG INDICATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; FEAR; NONHUMAN; RAT; STARTLE REFLEX; TRANQUILIZING ACTIVITY;

ANTI-ANXIETY AGENTS; ANXIETY; BRAIN; CALCIUM; CELL LINE; EXCITATORY AMINO ACID ANTAGONISTS; FEAR; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE; STARTLE REACTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037448394     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm025570j     Document Type: Article

References (22)

1. Ozawa, S.; Kamiya, H.; Tsuzuki, K. Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol. (Oxford) 1998, 54, 581-618.
2. Brauener-Osborne, H.; Egebjerg, J.; Nielsen, E. O.; Madsen, U.; Krogsgaard-Larsen, P. Ligands for Glutamate Receptors: Design and Therapeutic Prospects. J. Med. Chem. 2000, 43, 2609-2645.
3. Pin, J.-P.; Acher, F. The metabotropic glutamate receptors: Structure, activation mechanism and pharmacology. Curr. Drug Targets: CNS Neurol. Disord. 2002, 1, 297-317.
4. Conn, P. J.; Pin, J.-P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205-237.
5. Varney, M. A.; Gereau, R. W. I. Metabotropic glutamate receptor involvement in models of acute and persistent pain: Prospects for the development of novel analgesics. Curr. Drug Targets: CNS Neurol. Disord. 2002, 1, 283-296.
6. Brodkin, J.; Busse, C.; Sukoff, S. J.; Varney, M. A. Anxiolytic-like activity of the mGluR5 antagonist MPEP. A comparison with diazepam and buspirone. Pharmacol., Biochem. Behav. 2002, 73, 359-366.
7. Spooren, W. P. J. M.; Vassout, A.; Neijt, H. C.; Kuhn, R.; Gasparini, F.; et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. 2000, 295, 1267-1275.
8. Spooren, W. P. J. M.; Schoeffter, P.; Gasparini, F.; Kuhn, R.; Gentsch, C. Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur. J. Pharmacol. 2002, 435, 161-170.
9. Tatarczynska, E.; Klodzinska, A.; Chojnacka-Wojcik, E.; Palucha, A.; Gasparini, F.; et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 2001, 132, 1423-1430.
10. Klodzinska, A.; Tatarczynska E.; Chojnacka-Wojcik, E.; Pilc, A. Anxiolytic-like effects of group I metabotropic glutamate antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) in rats. Pol. J. Pharmacol. 2000, 52, 463-466.
11. Schulz, B.; Fendt, M.; Gasparini, F.; Lingenhohl, K.; Kuhn, R.; et al. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology 2001, 41, 1-7.
12. Chiamulera, C.; Epping-Jordan, M. P.; Zocchi, A.; Marcon, C.; Cottiny, C.; et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. 2001, 4, 873-874.
13. Varney, M. A.; Cosford, N. D. P.; Jachec, C.; Rao, S. P.; Sacaan, A.; et al. SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J. Pharmacol. Exp. Ther. 1999, 290, 170-181.
14. Gasparini, F.; Lingenhohl, K.; Stoehr, N.; Flor, P. J.; Heinrich, M.; et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999, 38, 1493-1503.
15. Gasparini, F.; Kuhn, R.; Pin, J.-P. Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Curr. Opin. Pharmacol. 2002, 2, 43-49.
16. O'Leary, D. M.; Movsesyan, V.; Vicini, S.; Faden, A. I. Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br. J. Pharmacol. 2000, 131, 1429-1437.
17. Movsesyan, V. A.; O'Leary, D. M.; Fan, L.; Bao, W.; Mullins, P. G. M.; et al. mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 2001, 296, 41-47.
18. See Supporting Information.
19. Varney, M. A.; Suto, C. M. Discovery of subtype-selective metabotropic glutamate receptor ligands using functional HTS assays. Drug Discovery Today: HTS Suppl. 2000, 1, 20-26.
20. Daggett, L. P.; Sacaan, A. I.; Akong, M.; Rao, S. P.; Hess, S. D.; et al. Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5. Neuropharmacology 1995, 34, 871-886.
21. 3H]-methoxy-PEPy): Potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) Receptor. Bioorg. Med. Chem. Lett., in press.
22. 3H]-Methoxymethyl-MTEP binding to metabotropic glutmate receptor subtype 5 in rat brain: in vitro and in vivo characterization. J. Pharmacol. Exp. Ther., in press.